Riskpilot← Back to searchSign inGet full accessBioPharmaLinx AB
ABActiveOrg 5567684401Research and experimental development on natural sciences and engineering · NACE 7210Est. 20080 employees
Revenue 2025
SEK 0
EBITDA margin
—
+24% vs 2024
Equity ratio
98.5%
Financial strength
Net profit 2025
SEK -26K
-107% vs 2024
| Revenue | SEK 0 | — |
| EBITDA | SEK -30K | +24% |
| Net profit | SEK -26K | -107% |
| Total assets | SEK 8,7M | -3% |
| Equity | SEK 8,5M | -3% |
| Employees | 0 | — |
Legal name
BioPharmaLinx AB
Org number
5567684401
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
31 oktober 2008
Share capital
SEK 120 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2025-08-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamöterna
Company purpose
Bolaget ska bedriva rådgivning samt analytisk och teknisk konsultation för utveckling av läkemedel, köp och förvaltning av lös och fast egendom samt därmed förenlig verksamhet.
Address
Email
karinsewerin@icloud.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 1 696 | 1 887 | 1 319 | 400 | 0 |
| Staff expenses | — | −430 | — | −269 | −0 |
| EBITDA | 715 | 375 | −366 | −40 | −30 |
| Depreciation & amort. | −132 | −122 | −110 | — | — |
| EBIT | 583 | 252 | −476 | −40 | −30 |
| Net financials | 218 | 45 | 11 | 7 | 5 |
| Profit before tax | 1 101 | 898 | 245 | 468 | −26 |
| Tax | −249 | −205 | −79 | −111 | — |
| Net profit | 852 | 693 | 166 | 356 | −26 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 10 054 | 10 226 | 9 358 | 8 932 | 8 658 |
| Equity | 8 111 | 8 620 | 8 599 | 8 760 | 8 530 |
| Long-term debt | 0 | — | 0 | — | — |
| Short-term debt | 133 | 396 | 259 | 173 | 128 |
| Total debt | 133 | 396 | 259 | 173 | 128 |
EBITDA margin
-3031200.0%
This company
15.8%
Market median
-19184910% vs market
20212025
Equity ratio
98.5%
This company
38.2%
Market median
+158% vs market
20212025
Return on equity
-0.3%
This company
18.4%
Market median
-102% vs market
20212025
Net profit margin
-2565400.0%
This company
8.1%
Market median
-31671705% vs market
20212025
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20212025
Debt / equity
0.02×
This company
0.62×
Market median
+97% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-09-01 – 2025-08-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-09-01 – 2024-08-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-09-01 – 2023-08-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-09-01 – 2022-08-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-09-01 – 2021-08-31
| Name | Role | Member since |
|---|---|---|
| Former (1) | ||
SK Audit | Audit | 2021 – 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (4) | ||
| Board of Directors | 2020 | |
| Deputy Board Member | 2020 | |
| Deputy Board Member | 2020 | |
| Chairman | 2020 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of BioPharmaLinx AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Sara Katarina Nyberg | Audit | 0 companies |
| Ulf Jan Peter Hedander | Board of Directors | 0 companies |
| Johan Linus Peter Hedander | Deputy Board Member | 0 companies |
| Karl Mikael Sewerin | Deputy Board Member | 0 companies |
| Karin Margareta Sewerin | Chairman | 0 companies |